Antibody Engineering for Pursuing a Healthier Future

Saeed, Abdullah F. U. H.; Wang, Rongzhi; Ling, Sumei; Wang, Shihua

Currently, mAb products approved by the US Food and Drug Administration (FDA) are increasing worldwide i.e., about four new products per year. Currently, 47 mAb products in the US, Europe and global markets have been approved for the treatment of a variety of diseases (Table 1 ; Ecker et al., 2015) . At the current rate, about 70 mAb products will be on the market by 2020, and collective global trade will be approximately $125 billion (Ecker et al., 2015) . Improvements in hybridoma technology are based on research demand, cost effectiveness, human labor, and reduced development time. Similarly, the production of mAbs requires multiple phases, long duration, and high cost. Currently, mAbs have been produced against a number of mycotoxins such as fumonisin B1 (Yuan et al., 2012; Ling et al., 2014 Ling et al., , 2015b , citreoviridin (Jin et al., 2014) , marine toxins (Saeed and Wang, 2016) , and other exo-and endo-antigens. Similarly, mAbs against transmembrane enzymes have been produced (Yuan et al., 2012) .